aTyr’s mission is to translate newly discovered biological pathways to develop innovative therapeutics with improved outcomes for patients.
Our focus is on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. Built on more than a decade of foundational science in this area, we have built a global intellectual property estate directed to all 20 human tRNA synthetases, with over 300 protein compositions patented.
Our lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP-2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. We are developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. We selected pulmonary sarcoidosis as our first ILD indication and are currently enrolling a Phase 1b/2a proof-of-concept multi-center, international clinical trial. The study has been designed to evaluate the safety, tolerability and immunogenicity of multiple doses of ATYR1923 and to evaluate established clinical endpoints and certain biomarkers to assess preliminary clinical activity of ATYR1923. The results of this study will guide future development of ATYR1923 in pulmonary sarcoidosis and provide insight for the potential of ATYR1923 in other ILDs such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD (CTD-ILD).
We are also advancing our pre-clinical pipeline of tRNA synthetases and NRP-2 targeting candidates through internal research efforts, industry and academic collaborations. In March 2019, we entered into a research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases. We are also working closely with other collaborators and academia to further research in these areas.
Source
